|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Sanofi
|
|
gptkbp:acquisition
|
gptkb:Aquila_Biolabs_Gmb_H
gptkb:Aderis_Pharmaceuticals
various biotech firms
|
|
gptkbp:awards
|
various industry awards
|
|
gptkbp:business_model
|
biopharmaceutical development
|
|
gptkbp:ceo
|
gptkb:Peter_Llewellyn-Davies
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
multiple ongoing trials
Phase I, II, and III
advanced stages
multiple phases conducted
MD G1011
MD G1021
MD G1031
various international sites
|
|
gptkbp:collaborations
|
gptkb:Max_Planck_Institute
gptkb:German_Cancer_Research_Center
gptkb:Heidelberg_University
gptkb:University_of_Munich
academic institutions
enhance research capabilities
joint ventures with universities
|
|
gptkbp:committee
|
composed of experts
|
|
gptkbp:community_engagement
|
active in local communities
|
|
gptkbp:employees
|
over 100
approximately 100
~100 (2021)
|
|
gptkbp:financial_performance
|
monitored regularly
published quarterly
|
|
gptkbp:focus
|
gptkb:vaccine
|
|
gptkbp:founded
|
gptkb:1994
|
|
gptkbp:future_plans
|
expand into new markets
|
|
gptkbp:governed_by
|
active in seeking partnerships
|
|
gptkbp:headquarters
|
gptkb:Planegg,_Germany
gptkb:Martinsried,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Medi Gene AG
|
|
gptkbp:invention
|
immunotherapy patents
numerous granted patents
biologics patents
protected by patents.
|
|
gptkbp:investment
|
transparent communication
biopharmaceutical research
institutional and private investors
diverse group
R& D investments
|
|
gptkbp:key_people
|
gptkb:Dr._Frank_Mathias
|
|
gptkbp:language_of_instruction
|
multiple drug candidates
|
|
gptkbp:location
|
gptkb:government_agency
|
|
gptkbp:market
|
gptkb:government_agency
gptkb:Europe
gptkb:United_States
growing presence in Europe
|
|
gptkbp:market_cap
|
varies with stock performance
|
|
gptkbp:marketing_strategy
|
focus on niche markets
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:temple
gptkb:Roche_Holding_AG
gptkb:Novartis_AG
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer_Inc.
gptkb:Sanofi_S._A.
Merck K Ga A
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:platform
|
proprietary technologies
|
|
gptkbp:products
|
gptkb:Endo_TAG-1
gptkb:Onco_One
ongoing innovation
T cell therapies
T cell therapy
T cell receptor therapy
DC vaccine
|
|
gptkbp:publishes
|
numerous publications
|
|
gptkbp:receives_funding_from
|
secured from various sources
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:European_Medicines_Agency
adheres to regulations
various approvals
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
focused on innovative therapies
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
cell-based therapies
|
|
gptkbp:revenue
|
varies annually
€20 million (2020)
|
|
gptkbp:social_responsibility
|
engaged in CSR initiatives
|
|
gptkbp:strategic_importance
|
expand product portfolio
|
|
gptkbp:subsidiary
|
gptkb:Medi_Gene_Inc.
|
|
gptkbp:sustainability
|
environmentally conscious practices
|
|
gptkbp:symbol
|
MD G1
|
|
gptkbp:technology
|
T cell receptor technology
antigen-specific immunotherapy
|
|
gptkbp:traded_on
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:treatment
|
multiple cancer types
measured in trials
|
|
gptkbp:type
|
gptkb:Company
|
|
gptkbp:type_of_care
|
focus on patient needs
|
|
gptkbp:website
|
www.medigene.com
|